A retrospective study of use of sequential immunotherapy compared to dual immunotherapy as treatment in metastatic melanoma patients
Latest Information Update: 11 Jan 2022
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 11 Jan 2022 New trial record